Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Verition Fund Management
AddedFeb 13, 2024
UpdatedJun 28, 2026
Verition Fund Management

Verition Fund Management

Operating

Verition: A multi-strategy, multi-manager investment platform with a team of expert portfolio managers.

Location
Greenwich, CT, US
Founded
2008
Firm
Compare
Portfolio
Employees
Website

Verition Fund Management LLC is a multi-strategy, multi-manager hedge fund that focuses on a diverse range of global investment strategies. These include Credit, Fixed Income & Macro, Convertible & Volatility Arbitrage, Event-Driven, Equity Long/Short & Capital Markets, and Quantitative Strategies. The firm typically participates in various investment rounds, including Series A, B, C, and D, with investments in companies raising significant capital.

Notable portfolio companies include Amylyx Pharmaceuticals, Biosplice Therapeutics, Evommune, Georgiamune, Korro Bio, and Vedanta Biosciences. Verition's team comprises experienced portfolio managers with backgrounds in proprietary trading desks and client account management. The firm's investment philosophy emphasizes diversified strategies aimed at driving absolute returns. Verition also offers unique value-add services through its multifaceted infrastructure, supporting portfolio companies with strategic insights and operational expertise.

Verition Fund Management - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments6
Current Portfolio Count6
Total Portfolio Exits0

Top Investment Stages

Series B2 (33.3%)
Series A1 (16.7%)
Series C1 (16.7%)
Series D1 (16.7%)
Series Unknown1 (16.7%)

Stage Mix

Series B 33%Series A 17%Series C 17%Series D 17%Series Unknown 17%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Georgiamune logo

Georgiamune

Evommune logo

Evommune

Korro Bio logo

Korro Bio

Vedanta Biosciences logo

Vedanta Biosciences

Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

Biosplice Therapeutics logo

Biosplice Therapeutics

Verition Fund Management - Similar Investment Firms

Verus International logo

Verus International

Veritus Holdings logo

Veritus Holdings

Verus logo

Verus

Verissimo Ventures logo

Verissimo Ventures

verissimo.vc

Tiger Management logo

Tiger Management

Veron International logo

Veron International

Vista Verde Group logo

Vista Verde Group

Verge Capital Management logo

Verge Capital Management

Point72 Asset Management logo

Point72 Asset Management

point72.com

Verance Capital logo

Verance Capital

verancecap.com

Vera Equity logo

Vera Equity

veraequity.com

Proof logo

Proof

proof.vc

Veritas Capital logo

Veritas Capital

veritascapital.com

R3 Venture Partners logo

R3 Venture Partners

Invicta Management logo

Invicta Management

Verition Fund Management - Classification

Also Known As
  • Verition Fund Management LLC
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 2 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
SIC
  • 6000Depository Institutions